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Abstract Medicating ADHD is a controversial subject
that was acutely inflamed in 1995 when high rates of
ADHD diagnosis and treatment were documented in
southeastern Virginia. Psychologists in southeastern Vir-
ginia formed a regional school health coalition to imple-
ment and evaluate interventions to address the problem.
Other professionals with strong ties to the pharmaceutical
industry launched ad hominem attacks on the coalition’s
research and work. These attacks contributed to the work
being terminated in 2005. In the ensuing years, ADHD
drug treatment continued to escalate. Today, the national
rate of ADHD diagnosis exceeds all reasonable estimates
of the disorder’s true prevalence, with 14 % of American
children being diagnosed before reaching young adulthood.
Notable key opinion leaders continue to claim that there is
no cause for concern, but with a message shift from ‘‘the
prevalence is not too high’’ to ‘‘high prevalence is not too
concerning.’’ This paper provides an object lesson about
how innovative research can be derailed to the detriment of
sound medical and mental health care of children when
industry interests are threatened. Tenure may be the only
option for protecting innovative research from specious
attacks. The authors offer a summary of the data on ADHD
drug treatments, suggest judicious use of such treatments,
and add their voices to others who are once again sounding
a cautionary alarm.
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Overview
In the mid-1990s, a practicing psychologist in southeastern
Virginia, Gretchen LeFever [i.e., Gretchen LeFever Wat-
son], began a program of ADHD research that included
epidemiologic surveys. This research documented excep-
tionally high rates of ADHD diagnosis and drug treatment
in her community. With support from Children’s Hospital
of The King’s Daughters and Eastern Virginia Medical
School (EVMS), LeFever formed a regional school health
coalition to improve ADHD treatment. Based on com-
munity input, she and her colleagues developed a sys-
tematic public health approach to improving the
identification and care of children with behavioral prob-
lems in the region.
In the course of this work, LeFever was repeatedly
attacked for reporting high rates of ADHD diagnosis and
treatment. One of the attacks came in the form of an
anonymous allegation of scientific misconduct and resulted
in the premature termination of LeFever’s work, including
her part of a multi-site, multi-million dollar study funded
by the Centers for Disease Control and Prevention (CDC)
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(Lenzer 2005a, b). The anonymous letter alleged that Le-
Fever had falsely reported high rates of ADHD diagnosis to
suit her own personal anti-medication agenda. Besides the
outright fallaciousness of the anonymous charge, there was
then—and is now—ample evidence to support LeFever’s
findings regarding high rates of ADHD diagnosis and drug
treatment. Nonetheless, the ad hominem attacks had a
damaging impact.
First, the attacks contributed to the suppression of a
large and unique dataset of risk and protective factors
associated with ADHD diagnosis and treatment. Second,
the attacks led to the total dismantling of a school health
coalition and associated behavioral and public health
interventions that showed promise for improving ADHD
care.
LeFever’s ‘‘Controversial’’ Findings
The long-standing ADHD debate had experienced a period
of relative quiet until LeFever and colleagues documented
high rates of ADHD drug treatment in the mid-1990s. They
found that 8–10 % of children in southeastern Virginia,
including 17 % of white boys, were being medicated in
school for ADHD (LeFever et al. 1999). In one district,
63 % of children who were young for their grade were
medicated for ADHD—suggesting a widespread failure to
distinguish between disorder and developmentally normal
variation. These findings were based on a large-scale and
rigorous epidemiologic study of 29,734 children and were
published in a prestigious journal—the American Journal
of Public Health (AJPH) (LeFever et al. 1999). The study
drew national and international media attention. LeFever
and colleagues conducted a follow-up study that was
expanded to include rates of ADHD diagnosis and drug
treatment that were not captured by school nurse records
(LeFever et al. 2002).
Whether relying on school nurse records or parent
report, approximately 9 % of students received a dose of
ADHD medication in school during regular school hours
(LeFever et al. 2002). However, twice as many children
had ADHD according to parent report compared to school
nurse records—namely, 17 % of all students in grades two
through five and 19 % in grades one through five (LeFever
et al. 2003). Among the 17 % of students whose parents
said they had ADHD, 84 % had also taken medication for
the disorder. Over one-quarter of these students were tak-
ing two or more types of psychotropic drugs simulta-
neously—the most common drug combination involved a
psychostimulant like Ritalin or Adderall and an antide-
pressant like Prozac. Rates were three times as high among
boys compared to girls, and twice as high among white
children compared to black children. As such, 33 % of
white boys (grades 2–5) were purported to have ADHD.
Despite high rates of drug treatment among children
identified as having ADHD, their educational outcomes
were poor. The students who with reported ADHD were
3–7 times more likely than their peers to experience
adverse educational outcomes as defined by repeating a
grade, needing special education services, and being
expelled and/or suspended. Outcomes were significantly
worse among students who had been medicated for ADHD
compared to those with ADHD and never medicated for the
condition (LeFever et al. 2002). As provocative as these
findings might seem, it was ultimately LeFever’s reporting
of high rates of drug treatment that were called into
question.
Summary of the Dismantled Public Health Approach
to Improving ADHD Care
The School Health Initiative for Education (SHINE) was a
regional coalition that LeFever formed in partnership with
diverse providers, policy makers, parents, and other com-
munity members (LeFever et al. 1999). Through regular
meetings that were open to the public, the coalition facil-
itated and conducted parent, teacher, and provider surveys,
focus groups, key informant interviews, and analysis of
new and extant databases. Based on an extensive com-
munity needs assessment, the coalition identified four
major gaps in ADHD care: (1) systematic behavior man-
agement, (2) school-provider communication, (3) teacher
training and education, and (4) parent training and support
(LeFever et al. 2000). LeFever obtained local, state, and
federal grant support to implement and evaluate the
effectiveness of interventions for each of the community’s
self-identified gaps.
With funding from the U.S. Department of Education,
LeFever and colleagues implemented a school-wide posi-
tive discipline program that resulted in ADHD symptoms
decreasing among an elementary school population from
the beginning to the end of the school year. This study also
documented that teachers who adopted positive classroom
management strategies—as evidenced by objective
behavioral ratings that achieved a 95 % inter-rater reli-
ability—had students who scored significantly higher on
every subject area of the Standards of Learning tests
administered to public school students across the state of
Virginia (LeFever and Allen 2004; LeFever et al. 2004).
With funding from the Virginia Department of Educa-
tion, LeFever and colleagues developed a program to
facilitate communication—with parental permission—
between parents and providers of children who were
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diagnosed with and/or treated for ADHD. The coalition
also developed a single-page ADHD Diagnostic Checklist
to remind or apprise parents, school personnel, and pro-
viders of the necessary steps to completing a comprehen-
sive ADHD diagnostic assessment process. SHINE
members also successfully developed a bill that was passed
by the Virginia legislature that prohibited teachers from
recommending ADHD medication to parents (LeFever
2008).
Interestingly, parents in the region reported greater sat-
isfaction with behavioral interventions than drug treatment,
although their children were far more likely to receive drug
treatment than other interventions (LeFever 2008). To
expand participation in parent training, LeFever and col-
leagues used local, state, and federal funding to develop
and implement a unique approach to marketing parenting
classes. The program—the A? Behavior Program: Help-
ing Your Student Excel in School and at Home—experi-
enced unprecedented levels of parent participation. It was
so well received that five school districts in southeastern
Virginia arranged for their psychologists to receive training
and supervision to deliver the program across the region.
Some of the participants in this train-the-trainer program
were affiliated with a clinical psychology internship that
offered a public health psychology tract that LeFever,
along with Virginia Beach City Public Schools, spear-
headed and led to become the first-ever public health
psychology internship in the country—a program that was
approved by the American Psychological Association
(APA).
These community-oriented interventions appeared to be
making a difference. Between 1998 and 2004, southeastern
Virginia witnessed a significant (32 %) decrease in the rate
of ADHD diagnosis. Among children in first through fifth
grade, it declined from a high of 19 % in 1998 to 13 % in
2004 (LeFever and Allen 2004). Unfortunately, the APA-
approved internship in public health psychology, the
SHINE Coalition, and projects described above were ter-
minated as a result of unjustified attacks on LeFever’s
research findings.
The Allegation of Scientific Misconduct
Although LeFever was never allowed to see the anonymous
and type-written allegation of scientific misconduct that
was lodged against her, she was informed that the gist of
the allegation was that she had intentionally inflated rates
of ADHD diagnosis and treatment to suit her own anti-
medication agenda. Reportedly, the allegation made ref-
erence to a figure of 17 % that was reported in one of her
publications. The figure of 17 % appears in more than one
publication and it was never made clear which publication
was being called into question. The anonymous complaint
also reportedly alleged that LeFever was conducting
research without proper consent. All of LeFever’s research
had been properly submitted to and reviewed by the
Institutional Review Board at EVMS where she was
employed. For the record, LeFever did not have an anti-
medication agenda and had been involved with the referral
of many children for medication evaluations.
As outlined below, the allegation and corollary reper-
cussions led the medical school to threaten to fire LeFever.
Thirty-nine psychiatrists and psychologists responded in
outrage by signing a petition expressing to the EVMS Dean
that LeFever should have been commended and promoted
for having the courage to be among the first to sound the
alarm (Lenzer 2005b). LeFever was eventually cleared of
all charges of scientific misconduct, honored with a sab-
batical, and supported by the Dean for promotion to Full
Professor (Lenzer 2005a). Nonetheless, the ‘‘chopping
block’’ experience ‘‘derailed’’ LeFever’s career (Whitaker
2010).
Orchestrated Attacks on Health Researchers
Attacks on health researchers who are at odds with the
pharmaceutical industry are not new (Healy 2002). As noted
in a New England Journal of Medicine article (Deyo et al.
1997), there is a pattern to such attacks. Individuals who
initiate them have financial interests in maintaining the
legitimacy of a medical model of illness or a particular
treatment. They have used allegations of scientific miscon-
duct and the media, as well administrative and legal assaults,
to malign the integrity of researchers and their findings—all
of which LeFever experienced. The authors noted that in one
documented case, a trial lawyer sponsored a workshop
promoting the use of allegations of scientific misconduct as a
weapon for disputing unwelcome research findings.
Regarding ADHD research, LeFever is not the only
scientist who experienced malicious attacks. Nadine
Lambert, a renowned school psychologist, endured a sim-
ilar experience. Lambert created a stir when she reported to
the National Institutes of Health that children who were
treated with stimulant medications like Ritalin started
smoking cigarettes earlier, smoked more heavily, and were
more likely as adults to abuse cocaine than were those not
taking ADHD medications (Lambert 1999). These results
were based on the culmination of a 30-year longitudinal
study of 492 children—about half of which had been
diagnosed with ADHD. Like LeFever, Lambert was falsely
accused of scientific misconduct (Diller 2005). Although
eventually cleared, the allegation derailed her research—
research that was never resurrected before Lambert died in
a tragic 2006 head-on collision with a truck.
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These are not isolated incidents. There are many other
examples of scientists who have been harassed, bullied, or
had their jobs threatened because they stood up to industry
and refused to let data be buried our spun (Blumsohn 2006;
Healy 2002, 2008; Marks et al. 1993; Monbiot 2002;
Nathan and Weatherall 2002; Thompson et al. 2001).
Industry Support for LeFever’s Most Outspoken
National Critic
Over the years, LeFever’s most outspoken national critic has
been clinical psychologist Russell Barkley, Ph.D. Barkley is
known in the field as a key opinion leader. An industry-
sponsored ‘opinion leader’, or ‘key opinion leader’ refers to
someone who is an active media user and who interprets the
meaning of subject-specific information for the broader
public (Elliott 2010). The pharmaceutical industry makes
liberal use of key opinion leaders, and Barkley may be the
best-known ADHD key opinion leader the industry has
courted. Although such individuals can be patient advocates,
they run the risk of becoming a marketing spokesperson for
the industry—unwittingly or otherwise.
Barkley repeatedly criticized LeFever based on what he
has expressed to be the unpalatable nature of her findings
rather than offering substantive criticism of her research
methodology or data analysis. Given Barkley’s prominence
as an established and leading scientist and clinician in the
field of ADHD, his comments about exaggerated emerging
prevalence trends carried weight. It is unclear how many
people knew then (or realize now) the significance of the
fact that a sizeable proportion of Barkley’s taxable income
came from the pharmaceutical industry. Barkley’s own
website once showed, for example, that approximately 8 %
of his taxable income came from Eli Lilly alone. Eli Lilly
manufactures Strattera, a commonly prescribed medication
for ADHD. Other income categories that were explicitly
tied to the pharmaceutical industry accounted for approx-
imately 19 % of his income (LeFever 2007). Like other
ADHD opinion leaders, Barkley also has had extensive
support from Children and Adults with Attention-Deficit/
Hyperactivity Disorders (CHADD)—a prominent advo-
cacy group that is supported with funds from the manu-
facturers of ADHD medications.
Attacks on LeFever’s Research (1996–2004)
Barkley’s criticism of LeFever began as early as 1996
when LeFever first shared her findings of high ADHD drug
treatment rates (findings that would eventually be pub-
lished in AJPH) with leading healthcare providers in
southeastern Virginia. In response to growing concerns
about ADHD treatment trends, EVMS pediatric faculty
invited Barkley to address the topic as the keynote speaker
for the region’s annual pediatric meeting. The annual
professional meeting included a talk that was open to the
public. As a recognized authority on a topic of great con-
cern to the general public, Barkley drew a huge crowd for
his public address. Barkley contended that ADHD was a
genetic disorder that was not being overdiagnosed or
overtreated, but that most children with ADHD were not
receiving medication when they should have been (Tennant
1996).
Not long thereafter, LeFever’s supervisor—a pediatri-
cian whose medical practice involved extensive ADHD
referrals—attempted to intimidate LeFever by abruptly
cancelling all her patients, informing LeFever’s coworkers
that she no longer worked at the hospital, and presenting
her with an unsanctioned request that she resign immedi-
ately. Having caught wind of the event, the medical school
leadership required the physician to provide LeFever with a
written and verbal apology and invite her back to practice
with him. Instead, she accepted an offer from the medical
school’s Center for Pediatric Research to assume a full-
time research faculty position. Thus began the campaign to
discredit and silence LeFever.
Barkley returned to Hampton Roads in 2000 to debate
LeFever on the topic of medicating ADHD. She was
allotted 15 min to present; Barkley was given 45 min.
Barkley began his talk by asserting that LeFever was not a
scientist, summarily dismissing her research out of hand.
Just a few months later, Barkley again attempted to dis-
credit LeFever when LeFever was invited to join an APA
panel discussion on ADHD treatment solutions. The panel
was comprised of experts who had been working in the
field of ADHD much longer than LeFever, including Drs.
Peter Jensen who had recently stepped down from a lead
position at the National Institutes of Health, William Pel-
ham (MTA investigator and Professor at SUNY Buffalo),
Larry Diller (pediatrician and author of Running on Rita-
lin), Charles Cunningham (Professor at McMaster Uni-
versity and ADHD researcher), and, of course, Barkley
(perhaps the most widely recognized name in the ADHD
field). What ensued was not so much of a planned dis-
cussion of treatment solutions but, rather, a debate about
ADHD drug treatment trends.
The following year, in 2002, Barkley published a paper
declaring that individuals who questioned the rising rates
of ADHD diagnosis and treatment represented ‘‘social
critics and fringe doctors.’’ He invited at least 85 psy-
chologists and psychiatrists to co-sign the paper. In the
paper, which he titled the International Consensus State-
ment on ADHD, Barkley dismissed people who expressed
a point of view that was contrary to his as ‘‘tantamount to
declaring the earth [Earth] flat, the laws of gravity as
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debatable, and the periodic table a fraud’’ (Barkley and 84
other behavioral scientists 2002, p. 3).
The following year (2003) another international group
of mental health professionals responded by publishing a
critique of Barkley’s statement (Timimi et al. 2004). Their
critique began by asking why a group of eminent psychi-
atrists and psychologists would produce a consensus
statement that sought to forestall debate on the merits of
widespread ADHD diagnosis and drug treatment. They
asserted that shutting down debate prematurely was com-
pletely counter to the spirit and practice of science and
reminded readers that one generation’s most cherished
therapeutic ideas and practices are often repudiated by the
next generation, but not without leaving countless victims
in their wake. This critique referenced LeFever’s AJPH
study findings as evidence against Barkley’s ongoing
assertion that less than half the children who need ADHD
medication are receiving medications (Timimi et al. 2004).
Barkley responded strongly with a published rebuttal
(Barkley et al. 2004).
A Call for Investigating LeFever’s Findings through
the Academic Press (March 2004)
Barkley’s rebuttal to the Timimi et al. critique of his
consensus on ADHD (Barkley et al. 2004) failed to cite
numerous studies that supposedly supported his argument.
The one study that he did choose to identify was Tim
Tjersland’s doctoral dissertation. This dissertation study
was methodologically flawed and remains unpublished
nearly a decade after completion (Tjersland 2004). Barkley
misrepresented the dissertation research as a replication
study of LeFever’s AJPH research and inaccurately
reported that it found prevalence rates near three percent in
southeastern Virginia. Not only was Tjersland’s study not a
true replication study, it did not produce the findings that
Barkley described. If anything, Tjersland’s results corrob-
orated LeFever’s findings. Of note, Barkley himself was
part of Tjersland’s dissertation committee. Based on this
methodologically flawed and unpublished study, Barkley
claimed that LeFever’s findings from multiple peer-
reviewed and published studies were so questionable that
they ‘‘deserve investigation’’ (Barkley et al. 2004, p. 68).
Investigative Call was Answered (April 2004)
Within weeks of Barkley’s call for an investigation of Le-
Fever’s findings, someone submitted an anonymous com-
plaint about LeFever’s work to EVMS (i.e., the complaint
described above). In response, EVMS conducted an internal
investigation of LeFever’s past and current research.
Against EVMS policy and common protocol for investi-
gation of allegations of scientific misconduct, the medical
school confirmed to the media that LeFever was under
investigation.
Before LeFever was aware of the allegation of mis-
conduct, the medical school had conducted a review of
more than a decade of her research. The process identified
that there might be a typo between the wording of a survey
item and the manner in which the survey item was
described in the appendix of a published article. Until the
reported typo was brought to LeFever’s attention, neither
she nor any of her three co-authors had ever noticed the
discrepancy.
Definition of Scientific Misconduct
Scientific or research misconduct is defined as fabrication
or falsification of research, plagiarism, or other practices
that deviate significantly from what is commonly accepted
within the scientific community research. It does not per-
tain to honest error or differences in interpretations or
judgments of data (Office of Research Integrity 1997, p. 3).
LeFever Cleared of Misconduct Charges (July 2004)
LeFever felt that it was important to explore how the
identified error had occurred and what, if any, impact it had
on reported outcomes. She researched reasons for the dis-
crepancy and detailed them in a written report that was
submitted to the EVMS scientific misconduct committee
that had been convened for her case. She met with the
committee and medical school attorneys for several hours
of testimony—all of which was tape-recorded. Later that
day, LeFever was informed that the committee had unan-
imously determined that there was no evidence of scientific
misconduct and that the typo appeared to be an honest error
that had no impact on research conclusions. No finding of
misconduct was ever reported to the Office of Human
Research Protection, as would have been required if Le-
Fever had violated consent procedures.
The EVMS committee did ask LeFever to inform the
journal where the study with the typo had been published to
disclose the error. She did so forthwith and in writing. The
journal’s Editor determined that the typo was too minor to
warrant any corrective action. The matter should have been
dropped, but instead inquiries about consent procedures
and reported findings escalated.
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Reporter-Generated ‘‘Evidence’’ of ‘‘Misconduct’’
Although the journal determined that the error in LeFever’s
publication was too minor to warrant a corrective statement,
the Editor subsequently contacted LeFever to share that a
reporter (Bill Sizemore of The Virginian Pilot) had repeat-
edly asked her to publish the error statement. Phelps
lamented to LeFever that she and her co-Editor, who also felt
that the error was too minor to warrant any action, finally
decided to turn the matter over to the publishing house. The
journal’s publishing house decided for the sake of public
relations/business reasons—not for reasons pertaining to
scientific integrity—that they would publish a brief error
statement in the next issue of the journal (Phelps, personal
communication, January 2005; April 2007), which appeared
in a subsequent issue (LeFever et al. 2005).
Relentless and Prejudiced External Interference (April
2004–January 2005)
LeFever endured months of waiting for her name to be
cleared and research to be re-approved for continuation.
EVMS eventually cleared her of all charges of scientific
misconduct and re-approved her research for continuation.
However, that LeFever was under investigation became
common knowledge among the medical school staff and
faculty, community collaborators, city leaders, and the
press. The day after LeFever’s research was finally re-
approved for continuation, the approval was rescinded.
Apparently, this news also leaked out, and more complaints
about her research reportedly surfaced. LeFever never
learned exactly who complained about what, but she was
informed that all the concerns were investigated and dis-
missed as unfounded.
Eventually, a ‘‘research ethicist’’ by the name of Felix
Gyi, M.D. who had been communicating with EVMS was
asked to express his opinion directly to LeFever during a
conference call with her and EVMS administrators and
attorneys. Gyi was CEO of Chesapeake Research Review,
which is a for-profit company whose primary clients are
major pharmaceutical companies and universities con-
ducting research funded by the pharmaceutical industry.
Chesapeake Research Review was involved with at least
one ADHD drug trial involving both EVMS faculty and
Barkley. Gyi asserted that LeFever’s CDC-funded research
represented more than minimal risk to subjects and,
therefore, proper consent procedures had not been used. In
response, EVMS halted LeFever’s work.
On or about December 9, 2004, a Virginia Beach school
district official reportedly complained to the EVMS Dean
that LeFever had misled her about procedures to obtain
parental consent for her CDC-funded epidemiologic survey
study that was underway in area school districts. This
allegation was false and wholly unsupported by the record.
Fear on the part of school officials of possible legal action
and press scrutiny apparently created an atmosphere in
which the self-preservation instinct overcame solid factual
analysis of what transpired. The unsubstantiated claim by a
school official that she had been misled about LeFever’s
research protocol and consent procedures was the straw
that broke the camel’s back. The ordeal and looming threat
of a scandalous newspaper expose about local ADHD
research had the potential to become a public relations
nightmare for the medical school and collaborating school
districts. On December 14, 2004, the very newly appointed
and Interim Dean of the medical school (under advisement
from attorneys who may not have appreciated the full
academic impact of their legal positions) permanently
terminated LeFever’s research, placed her on administra-
tive leave (Lenzer 2005b) and wrote to public school
officials promising that the study data would never be used
for any purpose.
LeFever was Defamed in the Public Press (January
2005)
A long-anticipated newspaper ‘‘expose’’ of LeFever’s
‘‘wrongdoing’’ was finally published on January 25, 2005
(Sizemore 2005). The reporter failed to mention his role in
pressuring the journal to publish the statement despite the
fact that the editor had determined that it was unnecessary
and was inconsequential to the study’s findings and con-
clusions. This public relations fiasco effectively extin-
guished any chances of LeFever re-kindling relationships
that were vital to the continuation and success of her work.
As such, the article brought an end to ADHD research and
community-based interventions in southeastern Virginia—
work that might have served as a model for improving
mental health care in other communities dealing with high
rates of diagnosis and drug treatment. The newspaper story
quoted a local psychologist with ties to CHADD who was
concerned that LeFever’s work frightened parents away
from seeking appropriate treatment for their children and
Barkley who described LeFever’s findings as ‘‘highly sus-
picious’’ (Sizemore 2005). The net effect was that a decade
of LeFever’s research and community work described ear-
lier was dismantled, and the ADHD debate was significantly
quieted in the ensuing years.
Landslide Victory for Big Pharma
The pharmaceutical industry and its key opinion leaders
were apparently successful in quelling our nation’s
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concerns about high rates of ADHD drug treatment. Since
2005, we have witnessed a message shift from ‘‘the rate of
ADHD drug treatment is not too high’’ to ‘‘a high rate of
ADHD drug treatment is not too concerning’’ (Scudder
2011).
In the years following the shutdown of LeFever’s work,
CDC reports documented continual increases in the rate of
ADHD diagnosis and drug treatment (CDC 2010; Sondik
et al. 2012). The CDC has reported that 11 % of American
children are currently diagnosed with ADHD (CDC 2013)
and that 14 % will receive a diagnosis of ADHD before the
end of childhood (i.e., by 15–17 years of age) (CDC 2010).
This national rate of ADHD diagnosis is now up to 50 %
higher than the rate that was reported by LeFever in AJPH
over a decade ago (8–10 %)—the rate that once sparked
national and international debate. Calculations based on
2010 CDC data also suggest that nearly 20 % of American
boys are now diagnosed with ADHD by 15–17 years of age
(CDC 2013). Similar trends were found in 2011 (Sondik
et al. 2012). These reports and the most recent CDC data
(CDC 2013) also documented that ADHD diagnosis and
treatment rates continue to vary widely by geographic
region as documented more than a decade ago (e.g.,
Morrow et al. 1998). The most recent CDC data indicate
that ADHD is now the most prevalent mental health
diagnosis among children 3–17 years of age, with rates that
vary substantially by state (from a low of 5.6 % in Nevada
to a high of 15.6 % in North Carolina) (CDC 2013). Due to
within state variation, some communities probably have
experienced rates of diagnosis that are notably higher than
the national average of 14 % or the state high of 15.6 %.
Yet, there has been limited professional or public outcry
about the ever-rising rate of ADHD diagnosis and drug
treatment.
Rise of Ritalin is Replaced by the Rise of Risperdal
More disturbing than the high level of psychostimulant
drug treatment is the growing numbers of children who are
being prescribed an ever-widening formulary of powerful
psychotropic drugs to treat ADHD. For example, pre-
scriptions for antidepressants (which are often added to
psychostimulant treatment regimens for children with
ADHD have increased over 400 % in recent years (Pratt
et al. 2011). Antipsychotic drug prescriptions—prescrip-
tions for drugs like Risperdal that historically have been
reserved for treatment of adults with schizophrenia and
other psychotic disorders—increased eight-fold among
children during the last two decades (1993-2009) (Olfson
et al. 2012) with the nation’s poorest children among the
most common recipients (e.g., Zito et al. 2013). Data col-
lected between 2005 and 2009 reveal that, of all children’s
physician office visits, almost 2 % result in the prescription
of an antipsychotic drug. The rate is almost 4 % for ado-
lescents and skyrockets to 30 % when the visit involves a
psychiatrist (Olfson et al. 2012). Between 2005 and 2007,
the state of Florida witnessed a 250 % increase in the
prescription of antipsychotic drugs for children (Farley
2007). This included 1,100 Medicaid children as young as
3 years of age. Many such prescriptions are specifically for
children carrying a diagnosis of ADHD (Matone et al.
2012); others are likely prescribed for iatrogenic effects of
ADHD drug treatment (Whitaker 2010).
As alarming as these trends are in and of themselves,
there is yet another (and more disturbing) layer to the story
of ADHD treatment trends. Many children are being trea-
ted with more than one psychotropic drug at a time (Mo-
jtabai and Olfson 2010; Zonfrillo et al. 2005). If one drug is
dangerous on its own, certainly combining two drugs
increases the risk of harm exponentially. There is little
research clearly investigating these effects, but emerging
data suggests significant risk (Mojtabai and Olfson 2010;
Zonfrillo et al. 2005). The documented rate of diagnosis is
now so high and the use of a host of psychotropic drugs so
prevalent that it should raise concern among all healthcare
professionals, child advocates, and parents.
What’s the Harm of Casually Diagnosing
and Aggressively Medicating ADHD?
The more a drug is prescribed, the more it is available for
diversion and abuse. Research has shown that as early as
15 years ago in some communities, up to 16 % of ele-
mentary through high school students had been approached
by classmates to share or sell their ADHD medications
(Musser et al. 1998); 5 years later, up to 23 % of middle
and high school students had been approached (McCabe
et al. 2004). By 2006, 34 % of students attending a large
southeastern college reported using ADHD drugs illegally
(DeSantis et al. 2008). The ubiquitous availability of
ADHD medications on high school and college campuses
has led many teens and young adults to perceive drugs like
Adderall to be benign for academic enhancement (e.g.,
Desantis and Hane 2010; DeSantis et al. 2008, 2010; Wish
et al. 2005). They also view these drugs as relatively safe
for recreational use and freely mix them with alcohol (e.g.,
Desantis and Hane 2010; DeSantis et al. 2008)—a poten-
tially lethal combination. Growing numbers of students are
now sharing, swapping, stealing, and abusing ADHD
medications. Not surprisingly, increases in ADHD pre-
scriptions have been associated with a parallel escalation in
abuse of ADHD drugs.
Analysis of national poison control data for 1998–2005
showed a sharp increase in the number of children between
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13 and 19 years of age who were reported to poison control
due to ADHD medication abuse—an increase that was
disproportionately higher than drug abuse generally or for
teen substance abuse in particular (Setlik et al. 2009). The
severity of cases also increased over time, particularly for
amphetamines (e.g., Adderall) compared to methylpheni-
dates (e.g., Ritalin) (Substance Abuse and Mental Health
Services Administration 2013). Nationwide, emergency
department visits for adverse reactions to prescription use
of such drugs as well as illicit use of such drugs also
increased between 2005 and 2009 (National Institute of
Drug Abuse 2011).
Even when used as prescribed, ADHD drug treatment
often brings with it adverse side effects. The side effects
may include undermining of an individual’s motivation to
take other steps to address behavioral issues, deflating of
one’s sense of self-efficacy, and/or flattening of one’s
affect or natural exuberance. ADHD drugs also carry the
potential for side effects such as sleep disturbance and
growth suppression, as well as more serious side effects
like elevated risk for drug dependence, psychosis, cardiac
arrest, and violence against oneself or others (Moore et al.
2010). Between 2004 and 2011, there were more than
11,000 cases of psychotropic drug side effects related to
violent actions reported to the FDA’s MedWatch system.
And these are only the side effects that are reported to the
FDA, which constitute only an estimated 1–10 % of actual
occurrences.
Despite the fact the FDA requires that mainstream
ADHD stimulant drugs carry a ‘‘black box’’ warning label
noting the drugs’ risks for addiction, psychosis, and cardiac
arrest, many professionals, parents, and patients underes-
timate the power of prescription pills due to ‘‘successful’’
marketing campaigns (e.g., Lacasse and Leo 2009). Pop-
ular media have also aided the pharmaceutical industry’s
overselling of the benefits of ADHD drugs (Gonon et al.
2012). Findings that emerged from our country’s epic
MTA Study (Kollins et al. 2006; Richters et al. 1995)—a
large-scale, longitudinal study funded by the National
Institutes of Health—showed that: (a) the benefits of drug
treatment (even carefully monitored drug treatment) faded
over time while the benefits of behavioral treatment
endured (Pelham and Fabiano 2008); (b) drug treatment
was not effective as delivered as part of routine community
care (Greenhill et al. 2001); (c) drug treatments did not
result in better academic outcomes (Molina et al. 2009);
(d) over time, behavioral interventions were more effective
than drug treatment (Pelham and Fabiano 2008) and
(e) when behavioral interventions were implemented prior
to the initiation of drug treatment, 75 % of children fully
resolved their ADHD symptoms (Pelham 1999). Yet, the
pervasive public message was that ADHD drugs work and
should be the first line of defense (Pelham and Fabiano
2008). In fact—as is also the case with depression (An-
tonuccio 2008; Antonuccio et al. 1995, 1999, 2002)—the
scientific evidence indicates that psychosocial interven-
tions for ADHD are at least as effective as ADHD drug
treatment when long-term outcome is considered (for a
review, see Pelham and Fabiano 2008).
In addition to overselling drug benefits, the pharma-
ceutical industry minimizes drug risks (Lacasse and Leo
2009). Individuals who experience the side effects are
portrayed as biologically predisposed and/or otherwise
vulnerable to emotional breakdowns (e.g., Sizemore 2012).
Such generalizations can lull clinicians and parents into a
false sense of security and belief that the side effects will
not occur for otherwise ‘‘normal’’ children.
Summary
ADHD experts with ties to the pharmaceutical industry
and/or CHADD repeatedly launched ad hominem attacks
on work by a psychologist whose research findings con-
flicted with drug industry interests. These attacks ulti-
mately led to a decade of significant ADHD research and
community-based interventions being mischaracterized in
professional venues and media outlets. The net effect was
that research on psychosocial interventions that also raised
questions about the effectiveness of ADHD drug treatment
was terminated and study findings were suppressed. This
helped pave the way for continued escalation and expan-
sion of ADHD diagnosis and drug treatment among
American children, youth, and adults. The rate of ADHD
diagnosis now exceeds all reasonable estimates of the true
prevalence of the disorder. As a consequence, ADHD drugs
are readily available on American high school and college
campuses where they are increasingly abused with serious
and sometimes lethal consequences.
A Professional Call to Arms
With mounting evidence of serious risks associated with
widespread use of psychotropic drugs, the case of the
attack on LeFever and suppression of the data she gener-
ated can serve as a wake-up call for mental health pro-
fessionals. This case provides an object lesson about why
tenure is so important in protecting academic freedom.
Without tenure, the risks to the independent academician
can be great if billions of industry dollars may be threa-
tened (Antonuccio et al. 2003). It is up to independent
scientists to address the inflation of benefits of drug ther-
apies and the minimization of risk (Healy 2002, 2008; Leo
and Cohen 2003). Prominent Psychiatrist Allen Frances
and Psychologist Alan Stroufe have recently again sounded
50 J Contemp Psychother (2014) 44:43–52
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the alarm about ADHD being overdiagnosed, medications
being overused, and the lack of long-term benefit from
these medications (Frances 2013; Stroufe 2012). The
authors would like to add their voices to their call.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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